MXPA05002443A - Pirazolopiridinas y metodos para elaboracion y uso de las mismas. - Google Patents

Pirazolopiridinas y metodos para elaboracion y uso de las mismas.

Info

Publication number
MXPA05002443A
MXPA05002443A MXPA05002443A MXPA05002443A MXPA05002443A MX PA05002443 A MXPA05002443 A MX PA05002443A MX PA05002443 A MXPA05002443 A MX PA05002443A MX PA05002443 A MXPA05002443 A MX PA05002443A MX PA05002443 A MXPA05002443 A MX PA05002443A
Authority
MX
Mexico
Prior art keywords
pyrazolopyridines
making
methods
same
alk
Prior art date
Application number
MXPA05002443A
Other languages
English (en)
Inventor
Paula Boriack-Sjodin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MXPA05002443A publication Critical patent/MXPA05002443A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona compuestos de formula 1 que poseen afinidad inesperadamente elevada por Alk 5 y/o Alk 4 o ambos y pueden ser utiles como antagonistas de los mismos para evitar o tratar numerosas enfermedades que incluyen desordenes fibroticos. En una modalidad, la invencion describe un compuesto de formula 1.
MXPA05002443A 2002-09-06 2003-09-05 Pirazolopiridinas y metodos para elaboracion y uso de las mismas. MXPA05002443A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40881102P 2002-09-06 2002-09-06
PCT/US2003/027722 WO2004022054A1 (en) 2002-09-06 2003-09-05 Pyrazolopyridines and methods of making and using the same

Publications (1)

Publication Number Publication Date
MXPA05002443A true MXPA05002443A (es) 2005-09-30

Family

ID=31978684

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002443A MXPA05002443A (es) 2002-09-06 2003-09-05 Pirazolopiridinas y metodos para elaboracion y uso de las mismas.

Country Status (20)

Country Link
US (1) US7691865B2 (es)
EP (1) EP1551398A4 (es)
JP (1) JP2006502165A (es)
KR (1) KR20050057235A (es)
CN (1) CN1694698A (es)
AR (1) AR041207A1 (es)
AU (1) AU2003268447B2 (es)
BR (1) BR0314053A (es)
CA (1) CA2497970A1 (es)
EA (1) EA009441B1 (es)
GE (1) GEP20074125B (es)
IS (2) IS7726A (es)
MX (1) MXPA05002443A (es)
NO (1) NO20051503L (es)
NZ (1) NZ539069A (es)
PL (1) PL375699A1 (es)
RS (1) RS20050200A (es)
UA (1) UA80295C2 (es)
WO (1) WO2004022054A1 (es)
ZA (1) ZA200501856B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931589B2 (ja) * 2004-07-02 2012-05-16 正明 松岡 ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2083863B1 (en) 2006-10-03 2015-03-18 Genzyme Corporation Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
JP2010540451A (ja) * 2007-09-20 2010-12-24 ワイス・エルエルシー ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法
BRPI0909288A2 (pt) * 2008-03-14 2015-08-18 Otsuka Pharma Co Ltd Inibidores da mmp-2 e/ou da mmp-9
CN101544634B (zh) * 2008-03-27 2011-08-10 天津药物研究院 2-苯基-3-取代吡唑并[1,5-a]吡啶类衍生物及其制备方法和用途
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402335A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
BR112015022993B1 (pt) 2013-03-14 2021-12-14 Sumitomo Dainippon Pharma Oncology, Inc. Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes
MX369863B (es) 2013-08-23 2019-11-25 Neupharma Inc Ciertas entidades quimicas, composiciones y metodos.
EP3087069B1 (en) 2013-12-23 2019-01-30 Norgine B.V. Compounds useful as ccr9 modulators
EA031639B1 (ru) * 2014-03-27 2019-01-31 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-а]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ И 2,3-ДИГИДРО-1H-ИМИДАЗО[1,2-b]ПИРАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
EP3497087B1 (en) * 2016-08-15 2021-11-10 Neupharma, Inc. Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN112707902B (zh) * 2020-03-23 2022-04-15 杭州阿诺生物医药科技有限公司 TGF-β受体抑制剂

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6369068B1 (en) * 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
WO1997001575A1 (fr) 1995-06-29 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Substance wf16616, procede de production et utilisation
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
JP2000503302A (ja) 1996-01-11 2000-03-21 スミスクライン・ビーチャム・コーポレイション 新規置換イミダゾール化合物
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0885217A4 (en) 1996-02-01 1999-04-21 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
JP2000507224A (ja) 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Ｃｓａｉｄ化合物の血管形成の抑制物質としての使用
EP0888335A4 (en) * 1996-03-13 2002-01-02 Smithkline Beecham Corp NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
EP0889887A4 (en) * 1996-03-25 2003-06-11 Smithkline Beecham Corp TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES
EP0889888A4 (en) 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en) * 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP3418624B2 (ja) * 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド サイトカイン阻害活性を有する置換イミダゾール類
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DK0948495T3 (da) * 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU7138298A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
JP4380803B2 (ja) * 1997-06-12 2009-12-09 アベンテイス・フアルマ・リミテツド イミダゾリル−環式アセタール
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
KR20010014288A (ko) * 1997-06-30 2001-02-26 오르토-맥네일 파마슈티칼, 인코퍼레이티드 염증성 질환의 치료에 유용한 2-치환된 이미다졸
US6562832B1 (en) * 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CA2341370A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
EP1126852B1 (en) * 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
JP4632544B2 (ja) * 1998-12-25 2011-02-16 あすか製薬株式会社 アミノピラゾール誘導体
DE60003025T2 (de) * 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
EP1169317B1 (en) 1999-04-09 2003-01-15 SmithKline Beecham Corporation Triarylimidazoles
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
ATE296820T1 (de) 1999-06-03 2005-06-15 Teikoku Hormone Mfg Co Ltd Substituierte pyrazol-derivate
ES2260033T3 (es) * 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030109428A1 (en) * 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
AR029423A1 (es) 1999-12-21 2003-06-25 Sugen Inc Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
WO2001066539A1 (en) 2000-03-06 2001-09-13 Smithkline Beecham P.L.C. Imidazol derivatives as raf kinase inhibitors
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
JP4722318B2 (ja) * 2000-06-05 2011-07-13 ローム株式会社 チップ抵抗器
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
AU2001266611A1 (en) * 2000-06-01 2001-12-11 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
DE60120193T2 (de) 2000-09-15 2007-03-29 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinasehemmer
EP1318992B1 (en) * 2000-09-21 2005-07-27 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors
DE60111417T2 (de) 2000-10-18 2006-03-16 Ortho-Mcneil Pharmaceutical, Inc. Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
AU2002225730A1 (en) * 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
JP4217480B2 (ja) * 2000-11-20 2009-02-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
CN1274690C (zh) * 2000-12-28 2006-09-13 小野药品工业株式会社 三杂环化合物和包括其作为活性组分的药物
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
MXPA03009846A (es) 2001-04-27 2004-05-05 Vertex Pharma Derivados de triazol inhibidores de cinasa y usos de los mismos.
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) * 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
GB0127433D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
ES2292839T3 (es) * 2001-12-11 2008-03-16 Smithkline Beecham Corporation Derivados de pirazolo-piridina como agentes contra el herpes.
EP1511738A4 (en) * 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
US7365066B2 (en) * 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
ES2323421T3 (es) * 2002-09-18 2009-07-15 Pfizer Products Inc. Nuevos compuestos de oxazol como inhibidores del factor de crecimientotransformador (tgf).
EA200500378A1 (ru) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf)
US7361669B2 (en) 2003-01-02 2008-04-22 Millennium Pharmaceuticals, Inc. Compositions and method for inhibiting TGF-β
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
ZA200602755B (en) 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
IS7725A (is) 2005-03-04
EP1551398A1 (en) 2005-07-13
RS20050200A (en) 2007-08-03
BR0314053A (pt) 2005-07-19
EA200500450A1 (ru) 2005-08-25
AR041207A1 (es) 2005-05-11
AU2003268447A1 (en) 2004-03-29
EA009441B1 (ru) 2007-12-28
ZA200501856B (en) 2006-04-26
KR20050057235A (ko) 2005-06-16
WO2004022054A1 (en) 2004-03-18
NZ539069A (en) 2007-03-30
CA2497970A1 (en) 2004-03-18
PL375699A1 (en) 2005-12-12
NO20051503D0 (no) 2005-03-21
AU2003268447B2 (en) 2008-07-24
US20060106033A1 (en) 2006-05-18
CN1694698A (zh) 2005-11-09
US7691865B2 (en) 2010-04-06
UA80295C2 (en) 2007-09-10
NO20051503L (no) 2005-03-21
GEP20074125B (en) 2007-06-11
EP1551398A4 (en) 2006-06-07
IS7726A (is) 2005-03-04
JP2006502165A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
RS20050200A (en) Pyrazolopyridines and methods of making and using the same
RS20050616A (en) Pyrazoles and methods of making and using the same
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
HK1083838A1 (en) A2a adenosine receptor antagonists
HK1068136A1 (en) Muscarinic antagonists
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
DK1333833T3 (da) Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
GEP20084572B (en) Novel quinoline derivatives
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
MXPA02009549A (es) Imidazopiridinas triciclicas.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
MXPA04004980A (es) Antagonistas del receptor ccr-3.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.

Legal Events

Date Code Title Description
FG Grant or registration